Protease inhibitors: a tale of two companies

Article Abstract:

Merck and Abbott developed the protease inhibitors ritonavir and indinavir that when used with other anti-HIV drugs can reduce the amount of HIV in most infected people to levels that are not even detectable. The companies' different corporate, scientific and political strategies are examined.

Research, Product development, Drug therapy, HIV (Viruses), HIV, Protease inhibitors, Antiviral agents, ABT, Merck & Company Inc., Abbott Laboratories (Abbott Park, Illinois)

---

Exclusive license rankles genome researchers

Article Abstract:

Stanford University made a controversial decision to sell an exclusive license to a machine that makes oligonucleotides to Protogene, which refuses to sell the machine. Researchers maintain the exclusive agreement is hampering genetic research.

Equipment and supplies, Licensing agreements, Intellectual property, Genetic research, Scientific equipment, Stanford University, Scientific equipment and supplies, Protogene Laboratories Inc.

---

Similar abstracts:

• Abstracts: Glossy strategic plan hits the streets. Center for the mind pleases the senses. Childhood vaccines: the R&D factor
• Abstracts: Atrazine found to cause chromosonal breaks. New method measures exposure to volatile organics. Recycling not profitable
• Abstracts: Maintaining a Nuclear Deterrent Under the Test Ban Treaty. Minerals in the deep Earth: a message from the asteroid belt
• Abstracts: Stochastic aspects of matrix cracking in brittle matrix composites. Finite element simulations of fiber pull-out
• Abstracts: Applicability of Neuber's rule to the analysis of stress and strain concentration under creep conditions. Compressive failure of fiber composites: the roles of multiaxial loading and creep

This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.